Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),

Read more

FDA approves ViiV Healthcare’s dolutegravir tablet for children living with HIV

ViiV Healthcare Friday said that the US Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension, used combined with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain young patients.

Read more

BioNTech, Fosun Pharma, Pfizer working on COVID-19 vaccine. Clinical testing in Germany in April

BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.

Read more